Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol

Shiro Hiramitsu1,2†‡, Tomonori Ishikawa3†‡, Wan-Ru Lee3, Tamor Khan1,2, Christine Crumbley1,2, Nimra Khwaja1,2, Faezeh Zamanian1,2, Arvand Asghari1,2, Mehmet Sen2, Yang Zhang4, John R. Hawse5, John D. Minna6 and Michihisa Umetani1,2*  

1 Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX, United States, 2 Department of Biology and Biochemistry, College of Natural Sciences and Mathematics, University of Houston, Houston, TX, United States, 3 Division of Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, United States, 4 Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States, 5 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States, 6 Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, United States

27-hydroxycholesterol (27HC) is an abundant cholesterol metabolite in human circulation and promotes breast cancer cell proliferation. Although lung is one of the organs that contain high levels of 27HC, the role of 27HC in lung is unknown. In this study, we found that 27HC promotes lung cancer cell proliferation in an estrogen receptor β (ERβ)-dependent manner. The expression of 27HC-generating enzyme CYP27A1 is higher in lung cancer cells than in normal lung cells. Treatment with 27HC increased cell proliferation in ERβ-positive lung cancer cells, but not in ERα-positive or ER-negative cells. The effect on cell proliferation is specific to 27HC and another oxysterol, 25-hydroxycholesterol that has a similar oxysterol structure with 27HC. Moreover, among ligands for nuclear receptors tested, only estrogen had the proliferative effect, and the effect by 27HC and estrogen was inhibited by ERβ-specific, but not ERα-specific, inhibitors. In addition, the effect by 27HC was not affected by membrane-bound estrogen receptor GPR30. Interestingly, despite the high expression of CYP27A1, endogenously produced 27HC was not the major contributor of the 27HC-induced cell proliferation. Using kinase inhibitors, we found that the effect by 27HC was mediated by the PI3K-Akt signaling pathway. These results suggest that 27HC promotes lung cancer cell proliferation via ERβ and PI3K-Akt signaling. Thus, lowering 27HC levels may lead to a novel approach for the treatment of lung cancer.

Keywords: lung cancer, estrogen receptor, ERβ, 27-hydroxycholesterol, cholesterol metabolites

INTRODUCTION

Lung cancer is the leading cause of cancer deaths in men and women in the United States (1), and there is accumulating evidence that estrogen is a major driver of lung cancer (2). In addition, the proportional occurrence of histological lung carcinoma subtypes differs between men and women. While squamous cell carcinoma is the most common subtype in men, adenocarcinoma...
is the most common subtype in women (1, 3). Estrogen receptors, ERα and ERβ, are members of the nuclear receptor family, and are present both in normal lung tissue and lung tumors with ERβ as a dominant isoform (4–6). Large-scale randomized and observational studies showed that women who used hormone replacement therapy (HRT) including estrogen have a higher risk of adenocarcinoma than women who did not use HRT, and that risk of lung cancer was associated with chronic use of HRT (7). In contrast, breast cancer patients who received anti-estrogen treatment had significantly lower subsequent lung cancer mortality (8). Studies using genetically modified mice showed that both male and female lungs are highly estrogen-responsive (9, 10). Mice deficient in ERβ exhibited significant lung dysfunction both in males and females, indicating the importance of ERβ in the maintenance of lung function (11). Estrogens also stimulate growth and progression of lung tumors, and local production of estrogen in lung tissues by aromatase could affect lung tumor progression in ER(+) malignancies in men and women (12, 13). ER also interacts with epidermal growth factor receptors (EGFRs), and the combination of EGFR tyrosine kinase inhibitors and ER antagonists gives maximal inhibition of tumor cell proliferation in vitro and also anti-tumor activity in mouse tumor xenograft models in vivo (14, 15). Taken together, estrogen and ERs play important roles in lung cancer pathogenesis and treatment.

Oxysterols are metabolites of cholesterol that are produced in the liver and other peripheral tissues as a means to eliminate cholesterol (16). The most abundant circulating oxysterol is 27-hydroxycholesterol (27HC), and serum concentrations of 27HC correlate well with that of cholesterol. The levels of 27HC also rise progressively with age. The enzyme that generates 27HC, 7α-hydroxylase (CYP7B1), is primarily expressed in the liver, but also in peripheral tissues to a lesser extent (17). Using cell-based and in vitro assays, we discovered that 27HC is a competitive ER antagonist in the cardiovascular system (18). We further found that 27HC binds directly to ERα (κi = 1.32 µM) and ERβ (κi = 0.42 µM) in their ligand binding pockets, and it inhibits both transcriptional and non-transcriptional estrogen-dependent production of nitric oxide by vascular cells. In mice, elevated 27HC levels decreased ER-dependent expression of vascular nitric oxide synthase and repressed carotid artery reendothelialization after vascular injury. In addition to the anti-estrogenic effects of 27HC in vascular cells, we identified pro-estrogenic actions of 27HC in hepatoma HepG2 and colon cancer Caco-2 cells (18). Combinatorial peptide phage display revealed that 27HC induces a unique active conformation of ERα (19). In contrast to estrogens that have various levels of agonistic activity in all tissues, selective ER modulators (SERMs) are compounds that act as agonists or antagonists depending on the target genes and tissues (16). Although many compounds have been identified as SERMs, all of them were synthetic. Thus, 27HC is the first identified endogenously produced SERM, and has important biological actions in vitro and in vivo.

In breast cancer, in which ERα is classically involved in the development and progression of many tumors, paradoxically, post-menopausal women with decreased estrogen production are particularly at increased risk of ER-positive breast cancer. This risk occurs at a time when circulating estrogen levels are declining, and endocrine-based therapies against ER-positive breast cancer employing synthetic SERMs or aromatase inhibition are often ineffective or acquire resistance, suggesting other important unknown ER-mediated mechanisms (20). Once we identified 27HC as a novel endogenous SERM and that its abundance increases with age, we tested its potential actions on ER-positive breast cancer cells, and found that 27HC up-regulated ERα target gene expression and increased cell proliferation (19). Also in mice, 27HC promoted tumor growth and metastasis to the lung in an orthotropic breast tumor xenograft model (21). In humans, we found that elevated levels of 27HC in tumors, which are correlated with reduced expression of the 27HC-catalyzing enzyme oxysterol 7α-hydroxylase (CYP7B1), are associated with poorer patient survival (22). Even when age, tumor size, nodal status, and periperooperative therapy are taken into consideration, low expression of CYP7B1 continues to be associated with poor overall outcome. Thus, 27HC is a non-estrogen, locally-modulated, non- aromatized ER ligand that stimulates ER-positive breast tumor growth, and, most importantly, it is abundant in the microenvironment of tumors in women.

In the present study, we investigated how 27HC impacts lung cancer cell proliferation through its modulation of the ER-mediated action. We found that ERβ expression is higher in lung cancer cells than in normal lung cells, and also that 27HC promotes ERβ (+) lung cancer cell proliferation. Although lung cancer cells have elevated gene expression of 27HC-producing enzyme CYP7B1, endogenously produced 27HC was not the major factor involved in the 27HC-induced cell proliferation. We sought to determine the underlying mechanism, and found that the PI3K-Akt pathway is involved in the effect by 27HC on lung cancer cell proliferation.

MATERIALS AND METHODS

Materials

27HC was purchased from Avanti Polar Lipids. T0901317 (T1317) was purchased from Cayman Chemical. 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP), 4-[2-phenyl-5,7-bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP), G1, G15, and iressa were purchased from Tocris Bioscience. Cholestan-3β,5α,6β-triol and 5α-hydroxy-6-ketocholesterol were purchased from Steraloids. 17β-estradiol (E2), GW3965 (GW), 4β-hydroxycholesterol, 7-ketocholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 25-hydroxycholesterol, cholesterol 5α,6α-epoxide, cholesterol 5β,6β-epoxide, cholesterol, progesterone, 5α-dihydrotestosterone (DHT), dexamethasone, cortisone, Wy-14643, GW501516, troglitazone, EGF, insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), PD0325910, U0126, SB203580, LY294002, and clotrimazole were purchased from Sigma-Aldrich.
Gene Expression Analyses and Assessments of Gene Expression

Expression profiling of ERα, ERβ, CYP27A1, and CYP7B1 was part of a larger study (Gene Expression Omnibus DataSets accession number GSE32036) that has been previously published (23, 24). Raw data was background corrected with RMA, Log2 transformed, and summarized by medianpolish. Differently expressed genes were called using the LIMMA package and p-values were corrected for multiple testing with the Benjamini-Hochberg procedure. The expression heatmap was generated in R and ontology enrichment was performed in HOMER. CYP27A1, CYP7B1, ERα, and ERβ transcript abundance were further evaluated by quantitative RT-qPCR (25). Primer sequences used for RT-qPCR are listed in Supplemental Table 1.

Cell Culture Assays

MCF-7 (ATCC), A549 (ATCC), Lewis lung carcinoma (LLC, ATCC), H1395, and H596 cells were maintained in RPMI 1640 medium containing 5% FBS. Cell proliferation was assessed by quantifying 3H-thymidine incorporation (22). Cells were maintained in phenol red-free DMEM containing 5% charcoal-stripped FBS for 72 h. Cells were then counted into 24-well plates at a density of 100,000 cells per ml in media containing 5% charcoal-stripped FBS, and 24 h later they were treated with compounds for 24 h, during which 3H-thymidine incorporation was quantified. To provide a complementary approach in H1395 cells, in selected studies cell proliferation was quantified by cell number in selected studies cell proliferation was quantified by cell number. H1395 cells were transfected with an ERβ expression plasmid using Lipofectamine 2000 and used for the cell proliferation assay. To specifically evaluate the impact of silencing of CYP27A1 or CYP7B1 on the modulation of lung cancer cell proliferation, their expression was knocked down using dsRNA targeting human CYP27A1 (TF313602, Oligene Technologies), CYP7B1 (Dharmacon), or control dsRNA. H1395 cells were transfected with 50 nM RNA as described previously (25) and cell proliferation responses to vehicle or 27HC were evaluated from 48 to 72 h post-transfection.

Immunoblot Analyses

ER protein abundance was assessed by immunoblot analysis using antibodies against ERα (ab75635, Abcam), ERβ (26), and GAPDH (G8796, Sigma-Aldrich) as a control. Phosphorylation of ERK1/2, p38 MAPK, and Akt proteins were assessed by immunoblot with their phosphorylated protein-specific antibodies (Cell Signaling), and their total protein abundance was also assessed.

Statistical Analysis

All data are expressed as mean ± SEM. Two-tailed Student’s t-test or ANOVA was used to assess differences between two groups or among more than two groups, respectively, with Newman-Keuls post-hoc testing following ANOVA. P-values < 0.05 were considered significant.

RESULTS

Gene Expression of ER in Lung Cancer Cell Lines

To evaluate possible actions of 27HC in lung cancer pathogenesis, we determined the expression levels of CYP27A1, CYP7B1, ERα, and ERβ in a variety of lung cancer and normal lung cell lines. Ninety-one human lung tumor cell lines and 30 human normal bronchial epithelial cell lines from the Lung Cancer Program at UT Southwestern Medical Center were analyzed. With relative levels of expression represented as log2 (signal) in the heat diagram, mRNAs for CYP27A1 were detectable at varying levels with clear difference among the different cell types (Figure 1A). Thirty-one tumor cell lines showed moderate to high expression of 27HC-generating enzyme CYP27A1 while none of the normal cell line showed moderate to high CYP27A1 expression. The log2 CYP27A1 expression ratio of tumor vs. normal lung cells is 0.87 (P < 0.001). The mRNA expression for ERβ was also higher in tumor cells than normal lung cells (log2 ratio 0.28, P = 0.004). There were also varying levels of mRNA expression for CYP7B1 and ERα transcripts, although there is no significant difference between tumor vs. normal lung cells. We further validated the microarray data and also compared the mRNA expression levels in high ERβ expressed H1395, high ERα expressed H596, and ER-negative A549 cells with those in breast cancer MCF-7 cells by qRT-PCR analysis. As expected, MCF-7 cells have high mRNA expression of ERα. Consistent with the microarray results (Figure 1A), H1395 and H596 cells have high expression of ERβ and ERα, respectively (Figure 1B). The protein expression of ERα and ERβ was also confirmed in MCF-7 and H1395 cells, respectively (Figure 1C). The mRNA expression of CYP27A1 and CYP7B1 varied among cell lines, and the gene expression of aromatase, which converts testosterone to estrogen, was not observed in the cells tested (Supplemental Figure 1 and data not shown). These results suggest that the molecular machinery necessary to synthesize and metabolize 27HC is found in lung cancer cells, and local 27HC production and ERβ mRNA expression are higher in lung tumor cells than normal lung cells.

27HC Promotes H1395 Lung Cancer Cell Proliferation

Next, we evaluated whether 27HC has cell proliferative effects in lung cancer cells. We selected H1395 and H596 lung adenocarcinoma cells, which express high levels of ERβ and ERα, respectively and also A549 cells which have no expression of ER (Figure 1). 27HC and E2 induced cell proliferation of H1395, but not H596 or A549 cells (Figure 2A), suggesting that the effect by 27HC is ERβ-dependent. The proliferative effects of 27HC are also dose-dependent (Figure 2B) and specific to the 27HC structure, but not to general oxysterols. Among other oxysterols tested, only 27HC, and 25-hydroxycholesterol were able to induce cell proliferation in this model (Figure 2C). 25-Hydroxycholesterol has a similar oxysterol structure as 27HC and also acts as an ER ligand. We could not see any promoting effect on the cell proliferation by 4β-Hydroxycholesterol, 7-keto-cholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, cholesterol...
5α,6α-epoxide, cholesterol 5β,6β-epoxide, cholestane-3β,5α,6β-triol, and 5α-hydroxy-6-ketocholesterol, which are reported to stimulate breast cancer cell proliferation (27). These results indicate that 27HC promotes H1395 lung cancer cell proliferation and that the effect is specific to 27HC and 25-hydroxycholesterol.

Effects of 27HC on Lung Cancer Cell Proliferation Are ERβ-Specific

To examine whether the effect of 27HC on lung cancer cell proliferation was ERβ-specific, ligands for other nuclear receptors were tested on H1395 cells. Ligands for liver X receptor (LXR, T1317, GW), progesterone receptor (progesterone), androgen receptor (5α-dihydrotestosterone), glucocorticoid receptor (dexamethasone), mineralocorticoid receptor (cortisone), or α (Wy-14643), δ (GW501516), and γ (troglitazone) isoforms of PPAR in the concentrations known to activate their receptors (18) did not induce growth promoting effects in H1395 cells (Figure 3A). Together with the results in Figure 2C that 22(R)-hydroxycholesterol and 24(S)-hydroxycholesterol, which also act as ligands for LXR and retinoic acid related orphan receptors (RORs), respectively (28, 29), did not show any promoting effect on the H1395 cell proliferation, these results indicate that the effect by 27HC is not LXR-, PR-, AR-, MR-, GR-, PPAR- or ROR-dependent. Next, we used ER isoform-specific inhibitors. The effect by 27HC and E2 was inhibited by the ERβ-specific inhibitor PHTPP, but not by the ERα-specific inhibitor MPP (Figure 3B). To confirm the importance of ERβ in the 27HC-mediated lung cancer cell proliferation, we compared the effect by 27HC on LLC cells, which are ER-negative, and LLC cells that overexpress ERβ following transfection with an ERβ expression plasmid. 27HC and E2 induced cell proliferation of LLC cells that expressed ERβ, but had no effect on parental LLC cells (Supplemental Figure 2), further indicating that the effect by 27HC on lung cancer cell proliferation is ERβ-dependent. In addition to classical ER, estrogen can also activate the G protein-coupled receptor GPR30 (6). Thus, the involvement of GPR30 in the H1395 cell proliferation was tested using its agonist G1 and antagonist G15. Neither of these GPR30 ligands affected H1395 cell
proliferation and G15 did not abrogate the inducing effects of 27HC (Figure 3C), indicating that GPR30 is not involved in the 27HC-induced H1395 cell proliferation. These results indicate that 27HC promotes lung cancer cell proliferation via ERβ.

**Exogenous 27HC Is the Major Effector on ERβ (+) Lung Cancer Cell Proliferation**

Since lung tumor cells have higher expression of 27HC-generating CYP27A1 (Figure 1A), it is plausible that endogenous 27HC production affects ERβ (+) lung cancer cell proliferation. To examine the involvement of endogenous 27HC production in H1395 cell proliferation, we introduced shRNA against CYP27A1 into H1395 cells and generated clones A3 and D2. The shRNA decreased the expression of CYP27A1 significantly in two clones, A3 and D2 (Figure 4A); however, the cell proliferation was not altered in the presence of control or shRNA against CYP27A1 (Figure 4B). In a similar fashion, siRNA mediated suppression of CYP7B1, #32 and #33, significantly decreased CYP7B1 mRNA levels in H1395 cells (Figure 4C) but did not alter cell proliferation relative to control siRNA cells (Figure 4D). We further confirmed our findings using clotrimazole, an inhibitor of P450 enzymes to which both CYP27A1 and CYP7B1 belong, and the treatment of H1395 cells at 1 µM did not alter cell proliferation (Figure 4E). These results indicate that although lung cancer cells have high 27HC-generating enzyme expression, endogenous 27HC is not the major effector of ERβ (+) lung cancer cell proliferation.

**27HC Promotes Cell Proliferation Through the PI3K-Akt Pathway**

In addition to its action as a transcription factor, ER has an action as an extranuclear signaling molecule involving various kinase pathways such as PI3K-Akt and MEK-MAPK pathways. In non-small cell lung cancer, ER activation leads to the induction of the p44/p42 MAPK signaling pathway, which is considered to be an extranuclear action of ER (14). In addition, ER interacts with EGF receptor and activate tyrosine kinase signaling in breast cancer (15), and EGF, but not IGF or VEGF, promotes H1395 cell proliferation (Supplemental Figure 3A). To examine whether 27HC is capable of eliciting extranuclear effects, we performed immunoblot analysis using H1395 cell extracts. EGF stimulated the phosphorylation of p38 MAPK,
ERK1/2, and Akt in H1395 cells (Figure 5A). The treatment of 27HC also phosphorylated p38 MAPK and Akt, but not ERK1/2. Next, we performed cell proliferation assays in combination with kinase inhibitors. These inhibitors suppressed basal cell growth (Supplemental Figure 3C). The effect by 27HC was not inhibited by MEK/MAPK inhibitors PD0325901 or U0126 (Figure 5B). In contrast, the effect by 27HC was suppressed in the presence of the PI3K inhibitor LY294002. Interestingly, another p38MAPK inhibitor SB203580, which also inhibits Akt, suppressed the effect of 27HC. To examine the involvement of the EGFR signaling pathway in the ERβ-mediated 27HC effect on cell proliferation, EGFR inhibitor Iressa was also used. Iressa at 1 µM, which completely blocked the cell proliferation induced by EGF (Supplemental Figure 3B), did not alter the effects of 27HC (Figure 5B). These results suggest that 27HC promotes H1395 cell proliferation through the activation of PI3K-Akt signaling pathway in ERβ (+) lung cancer cells.

**DISCUSSION**

Although it is still controversial whether plasma cholesterol levels correlate with lung cancer risks, and also whether higher body mass index (BMI) is protective or harmful to lung cancer depends on cancer types, sex, and treatments (30–32), statins that lower cholesterol levels reduce the risk and mortality of lung cancer in human (33, 34), suggesting that lowering cholesterol levels, which also lowers 27HC levels, has a beneficial effect against lung cancer. Nevertheless, the precise mechanism of how cholesterol affects lung cancer pathogenesis, especially in relation with estrogen receptor status, still remains unknown. In addition, among many risk factors that may contribute to lung cancer incidence or mortality, endocrine factors including estrogen are critical modulators of lung cancer development and progression, and there is accumulating evidence that ERβ expression in conjunction with aromatase expression predicts survival in non-small cell lung cancer both in men and women (35, 36). Despite the poorly understood role of cholesterol in lung cancer pathogenesis, lung tissue has abundant levels of 27HC over a range of concentrations relevant to the modulation of ER function (18, 37). Additionally, protein expression of CYP27A1 is higher in lung tissues from chronic obstructive
pulmonary disease patients than normal lung tissues (38). With
the gene expression results showing that 27HC production and
ERβ expression is higher in lung tumor cells than in normal
lung cells (Figure 1), we determined if 27HC modifies lung
cancer cell proliferation, and found that 27HC promotes cell
proliferation of lung cancer cells that express ERβ. Although
some reports suggested that 27HC is a weak agonist for LXR
(39), 27HC does not activate LXR in the vascular system and
in liver (18). The effect of 27HC on H1395 cells was ERβ-
specific, and other nuclear receptor ligands tested did not show
proliferation-inducing effects (Figure 3). The effect of 27HC was
observed not only in H1395 cells, but also in LLC cells that
are transfected with ERβ (Supplemental Figure 1), indicating
the effect of 27HC is not H1395 cell-specific. Recently, a report
indicated that 27HC acts as a negative modulator of ERβ (40). In
our study, both 27HC and E2 promoted H1395 cell proliferation.
Considering estrogen always activates ER, 27HC likely has an
ERβ-mediated, pro-estrogenic function in lung cancer cells. Since
27HC shows both agonistic and antagonistic effects on ERα
function depending on target organs in our previous studies
(16), it is possible that 27HC may also function as both an
agonist and antagonist for ERβ in a cell/tissue type specific
manner.

Interestingly, although the expression of CYP27A1 is higher
in lung cancer cells than in normal lung cells (Figure 1),
endogenously produced 27HC did not alter lung cancer cell
proliferation in this study (Figure 4). The production of 27HC
in lung cancer cells was not be determined in this study, however,
there is accumulating evidence that CYP27A1 mRNA expression
correlates with its protein expression and enzymatic activity, and
also that CYP27A1 expression correlates with the levels of its
product 27HC in various types of cells and also in vivo (41–43).
In addition, to our knowledge, there is no other enzyme than
CYP27A1 known to endogenously produce 27HC in mammals.
Thus, it is reasonable to assume that higher CYP27A1 expression
reflects higher 27HC production in lung cancer cells, and also there
are reports showing effective CYP27A1 knockdown and
consequent decrease of its protein expression (44, 45). In breast
cancer, resident macrophages are important for generating and
providing 27HC to the microenvironment (21). In addition to the
key involvement of ERβ in lung tumor cells, ER activation
by 27HC in surrounding stromal cells may also contribute
importantly to oncogenesis, such as the regulation of host
immunity by estrogen, which is observed in breast tumor models
(46). Other possibilities include that the experimental condition
in this study was not suitable for detecting the subtle differences
caused by endogenously produced 27HC, and also that there
are some effects by endogenous 27HC other than those that we
examined. Further study will examine the role of endogenously
produced 27HC in lung cancer cells and the major source of
27HC involved in lung cancer cell proliferation.

In this study, we found that the effect of 27HC is stronger than
that of E2, even with superphysiological doses of E2 (Figure 2
and data not shown). Mechanistic studies indicated that the effect
of 27HC is mediated not by EGFR or MAPK, but by the PI3K-
Akt signaling pathway (Figure 5). We could not find evidence
that 27HC acts on pathways other than ER; however, there is
still a possibility that 27HC acts on unknown pathways, if any,
in addition to the ER signaling pathway. The PI3K-Akt signaling
pathway is involved in lung cancer progression (47), and 27HC
acts on the cardiovascular system through the activation of PI3K-
Akt signaling pathway (48). Further investigation on how 27HC
affects the PI3K-Akt signaling pathway are necessary to clarify
the role of PI3K-Akt signaling on lung cancer progression.

The novel nature of 27HC modulation of ERβ that we show in
this study has revealed a theoretical concept that links cholesterol
metabolism with lung cancer progression and treatment failure.
Such studies will further our understanding of lung tumor
pathogenesis and will further indicate the efficacy of 27HC-
directed therapeutic interventions for the treatment of this deadly
disease.

AUTHOR CONTRIBUTIONS

SH, TI, and MU designed the experiments. JM provided cell
lines. SH, TI, W-RL, TK, CC, NK, FZ, and AA performed the
experiments and acquired the data. SH, TI, MS, YZ, JH, JM,
and MU analyzed and interpreted the results, and MU wrote the
manuscript.

FUNDING

This work was supported by National Institutes of Health grants
P03DK079328 (MU) and UH CNRCS Startup Fund (MU).

ACKNOWLEDGMENTS

We thank Drs. Philip Shaull (UT Southwestern), Jan-Ake
Gustafsson (University of Houston) and their lab members,
Anders Strom, Surendra Chaurasiya, Shivangi Srivastava
(University of Houston), and Kendra Carmon (UT-Health) for
their technical help, thoughtful discussions, and suggestions.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2018.00470/full#supplementary-material

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. (2018)
68:7–30. doi: 10.3322/caac.21442

2. Siegfried JM, Stable L, P, Estrongenic steroid hormones in lung cancer. Semin
Oncol. (2014) 41:5–16. doi: 10.1053/j.seminoncol.2013.12.009

3. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E,
Bray F. International trends in lung cancer incidence by histological subtype:
adenoacarcinoma stabilizing in men but still increasing in women. Lung Cancer
(2014) 84:13–22. doi: 10.1016/j.lungcan.2014.01.009

4. Stable L, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafonda M, et al.
Combined analysis of estrogen receptor beta-1 and progesterone receptor
expression identifies lung cancer patients with poor outcome. Clin Cancer Res. (2011) 17:154–64. doi: 10.1186/1078-0432-CRR-10-0992
5. Schwartz AG, Prysk GM, Murphy V, Lonardo F, Pass H, Schwartz J, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res. (2005) 11:7280–7. doi: 10.1158/1078-0432.CCR-05-0498
6. Siegfried JM, Hersberger PA, Stabile LP. Estrogen receptor signaling in lung cancer. Semin Oncol. (2009) 36:524–31. doi: 10.1053/j.seminoncol.2009.10.004
7. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol. (2010) 28:1540–6. doi: 10.1200/JCO.2009.25.9739
8. Bouchardy C, Benhamou S, Schaffar R, Verkooijen HM, Fioretta G, Schubert H, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer (2011) 117:1288–95. doi: 10.1002/cncr.25638
9. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, et al. Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol. (2001) 15:1104–13. doi: 10.1210/mend.15.7.0658
10. Lemmen JG, Arends RJ, van der Saag PT, van der Burg B. Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol. (2004) 32:689–701. doi: 10.1677/jme.0.0320689
11. Morani A, Barros RP, Imamov O, Hultenby K, Arner A, Warner M, et al. Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta−/−) mice. Proc Natl Acad Sci USA. (2006) 103:7165–9. doi: 10.1073/pnas.0602194103
12. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human and non-small cell lung cancer cells. Steroids (2005) 70:372–81. doi: 10.1016/j.steroids.2005.02.017
13. Brodie A, Lu Q, Yue W, Wang J, Liu Y. Intratumoral aromatase model: the effects of letrozole (CCG 20267). Breast Cancer Res Treat. (1998) 49:523–6; discussion S33–7.
14. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. (2005) 65:1459–70. doi: 10.1158/0008-5472.CAN-04-1872
15. Marquez-Barcan DC, Chen HW, Fishbein MC, Goedlick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids (2007) 72:135–43. doi: 10.1016/j.steroids.2006.11.019
16. Umetani M. Re-adopting classical nuclear receptors by cholesterol metabolites. J Steroid Biochem Mol Biol. (2016) 157:20–40. doi: 10.1016/j.jsbmb.2015.11.002
17. Crisyb M, Nilsson J, Kostulas V, Bjorkhem I, Diczfalusy U. Localization of sterol 27-hydroxylase-immuno-reactivity in human atherosclerotic plaques. Biochim Biophys Acta. (1997) 1344:278–85.
18. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt J, et al. Increase of 27-hydroxycholesterol in the airways of patients with chronic lung disease. J Biol Chem. (2011) 286:1359–69. doi: 10.1038/nm1641
19. DuSell CD, Umetani M, Shaull PW, Mangelsdorf DJ, McDonnell DP. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. (2008) 22:65–77. doi: 10.1210/me.2007-0583
20. Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol. (2006) 102:323–40. doi: 10.1016/j.jsbmb.2006.09.012
21. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science (2013) 342:1094–8. doi: 10.1126/science.1241908
22. Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. (2015) 13:635–47. doi: 10.1016/j.celrep.2013.10.006
23. Kim J, McMillan E, Kim HS, Vunaksetarawan N, Makkar G, Rodriguez-Canales J, et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS−/− knockout (ERbeta−/−) breast cancer. J Mol Endocrinol. (2016) 157:20–6. doi: 10.1530/JME-15-0049.
24. McMillan EA, Ryu MJ, Diep CH, Mendiratta S, Clementeau JR, Vadnay RM, et al. Cholesterol-carboxylesterase-1 is a novel ascorbate transporter in primary human colon cancer cell lines. Biochim Biophys Acta. (2001) 1579:531–2. doi: 10.1016/S0304-4165(01)00053-4
44. Bingham TC, Parathath S, Tian H, Reiss A, Chan E, Fisher EA, et al. Cholesterol 27-hydroxylase but not apolipoprotein apoE contributes to A2A adenosine receptor stimulated reverse cholesterol transport. *Inflammation* (2012) 35:49–57. doi: 10.1007/s10753-010-9288-y

45. Fedorova OV, Zernetkina VI, Shilova VY, Grigorova YN, Juhasz O, Wei W, et al. Synthesis of an endogenous steroidal Na pump inhibitor marinobufagenin, implicated in human cardiovascular diseases, is initiated by CYP27A1 via bile acid pathway. *Circ Cardiovasc Genet.* (2015) 8:736–45. doi: 10.1161/CIRCGENETICS.115.001217

46. Curran EM, Judy BM, Duru NA, Wang HQ, Vergara LA, Lubahn DB, et al. Estrogenic regulation of host immunity against an estrogen receptor-negative human breast cancer. *Clin Cancer Res.* (2006) 12:5641–7. doi: 10.1158/1078-0432.CCR-05-1117

47. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget* (2011) 2:135–64. doi: 10.18632/oncotarget.240

48. Umetani M, Ghosh P, Ishikawa T, Umetani J, Ahmed M, Mineo C, et al. The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. *Cell Metab.* (2014) 20:1–11. doi: 10.1016/j.cmet.2014.05.013

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Hiramitsu, Ishikawa, Lee, Khan, Crumbley, Khwaja, Zamanian, Asghari, Sen, Zhang, Hawse, Minna and Umetani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*